Free Trial

ImmuPharma (LON:IMM) Shares Down 21.1% - Should You Sell?

ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's stock price fell by 21.1%, trading at GBX 11.76 after opening as low as GBX 10.80.
  • The company reported a negative PE ratio of -1,446.18 and a negative return on equity of 131.41% for the last quarter.
  • ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, P140 (Lupuzor™), aimed at treating Lupus and potentially other autoimmune diseases.
  • MarketBeat previews the top five stocks to own by October 1st.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was down 21.1% during trading on Thursday . The stock traded as low as GBX 10.80 ($0.15) and last traded at GBX 11.76 ($0.16). Approximately 45,915,910 shares changed hands during mid-day trading, an increase of 438% from the average daily volume of 8,530,393 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Price Performance

The firm's fifty day simple moving average is GBX 4.28 and its 200 day simple moving average is GBX 3.27. The company has a market capitalization of £62.47 million, a PE ratio of -1,404.49 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Stories

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.